These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

760 related articles for article (PubMed ID: 26750533)

  • 1. Stomatin-like protein 2 overexpression in papillary thyroid carcinoma is significantly associated with high-risk clinicopathological parameters and BRAFV600E mutation.
    Bartolome A; Boskovic S; Paunovic I; Bozic V; Cvejic D
    APMIS; 2016 Apr; 124(4):271-7. PubMed ID: 26750533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stomatin-like protein 2 is associated with the clinicopathological features of human papillary thyroid cancer and is regulated by TGF-β in thyroid cancer cells.
    Liu Z; Yang Y; Zhang Y; Ye X; Wang L; Xu G
    Oncol Rep; 2014 Jan; 31(1):153-60. PubMed ID: 24190591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAFV600E Mutational Status and Expression of Angiogenic Factors.
    Shi C; Guo Y; Lv Y; Nanding A; Shi T; Qin H; He J
    PLoS One; 2016; 11(12):e0167414. PubMed ID: 27936049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological characteristics of thyroid cancer in the federal state of Salzburg.
    Rendl G; Rodrigues M; Schweighofer-Zwink G; Hutter J; Hittmair A; Zellinger B; Hauser-Kronberger C; Pirich C
    Wien Klin Wochenschr; 2017 Aug; 129(15-16):540-544. PubMed ID: 28493027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma.
    Lukas J; Drabek J; Dudesek B; Vazan P; Stranska J; Jancik S; Mackova M; Syrucek M; Lukas D; Duskova J; Dundr P; Hintnausova B; Jiskra J
    Exp Clin Endocrinol Diabetes; 2014 May; 122(5):268-72. PubMed ID: 24839220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
    Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
    Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Follicular cell (papillary and follicular) thyroid carcinoma, genetic inheritance, and molecular diagnostic markers].
    Kazubskaia TP; Kozlova VM; Kondrat'eva TT; Pavlovskaia AI; Marakhonov AV; Baranova AV; Ivanova NI; Stepanova AA; Poliakov AV; Belev NF; Brzhezovskiĭ VZh
    Arkh Patol; 2014; 76(5):3-12. PubMed ID: 25543402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strong immunoexpression of midkine is associated with multiple lymph node metastases in BRAFV600E papillary thyroid carcinoma.
    Choi YW; Kim YH; Lee J; Soh EY; Park TJ; Kim JH
    Hum Pathol; 2015 Oct; 46(10):1557-65. PubMed ID: 26297257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Caveolin-1 expression in papillary thyroid carcinoma: correlation with clinicopathological parameters and BRAF mutation status.
    Paskaš S; Janković J; Marečko I; Išić Denčić T; Tatić S; Cvejić D; Savin S
    Otolaryngol Head Neck Surg; 2014 Feb; 150(2):201-9. PubMed ID: 24255086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients.
    Yip L; Nikiforova MN; Yoo JY; McCoy KL; Stang MT; Armstrong MJ; Nicholson KJ; Ohori NP; Coyne C; Hodak SP; Ferris RL; LeBeau SO; Nikiforov YE; Carty SE
    Ann Surg; 2015 Sep; 262(3):519-25; discussion 524-5. PubMed ID: 26258321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How Many Papillae in Conventional Papillary Carcinoma? A Clinical Evidence-Based Pathology Study of 235 Unifocal Encapsulated Papillary Thyroid Carcinomas, with Emphasis on the Diagnosis of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features.
    Xu B; Serrette R; Tuttle RM; Alzumaili B; Ganly I; Katabi N; Tallini G; Ghossein R
    Thyroid; 2019 Dec; 29(12):1792-1803. PubMed ID: 31452453
    [No Abstract]   [Full Text] [Related]  

  • 12. The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAFV600E Mutation Status and Other Prognostic Factors.
    Czarniecka A; Kowal M; Rusinek D; Krajewska J; Jarzab M; Stobiecka E; Chmielik E; Zembala-Nozynska E; Poltorak S; Sacher A; Maciejewski A; Zebracka-Gala J; Lange D; Oczko-Wojciechowska M; Handkiewicz-Junak D; Jarzab B
    PLoS One; 2015; 10(7):e0132821. PubMed ID: 26177218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
    Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
    Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated BANCR expression levels have different effects on papillary thyroid carcinoma progression depending on the presence of the BRAFV600E mutation.
    Stojanović S; Šelemetjev S; Đorić I; Rončević J; Janković Miljuš J; Živaljević V; Išić Denčić T
    Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1835-1842. PubMed ID: 32651027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of plasma BRAF(V600E) mutation is associated with lung metastasis in papillary thyroid carcinomas.
    Kim BH; Kim IJ; Lee BJ; Lee JC; Kim IS; Kim SJ; Kim WJ; Jeon YK; Kim SS; Kim YK
    Yonsei Med J; 2015 May; 56(3):634-40. PubMed ID: 25837167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-Analyses of Association Between BRAF(V600E) Mutation and Clinicopathological Features of Papillary Thyroid Carcinoma.
    Zhang Q; Liu SZ; Zhang Q; Guan YX; Chen QJ; Zhu QY
    Cell Physiol Biochem; 2016; 38(2):763-76. PubMed ID: 26871894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAFV600E Immunohistochemistry in Papillary Thyroid Carcinomas: Relationship Between Clinical and Morphological Parameters.
    Kombak FE; Özkan N; Uğurlu MÜ; Kaya H
    Turk Patoloji Derg; 2019; 35(2):83-91. PubMed ID: 30632125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.
    Liu X; Qu S; Liu R; Sheng C; Shi X; Zhu G; Murugan AK; Guan H; Yu H; Wang Y; Sun H; Shan Z; Teng W; Xing M
    J Clin Endocrinol Metab; 2014 Jun; 99(6):E1130-6. PubMed ID: 24617711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular characterization of tumors meeting diagnostic criteria for the non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP).
    Pool C; Walter V; Bann D; Goldenberg D; Broach J; Hennessy M; Cottrill E; Washburn E; Williams N; Crist H; Imamura Y; Warrick JI
    Virchows Arch; 2019 Mar; 474(3):341-351. PubMed ID: 30645670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF V600E mutation in papillary thyroid carcinoma: significant association with node metastases and extra thyroidal invasion.
    Chakraborty A; Narkar A; Mukhopadhyaya R; Kane S; D'Cruz A; Rajan MG
    Endocr Pathol; 2012 Jun; 23(2):83-93. PubMed ID: 22105775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.